Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EFFEXOR XR

« Back to Dashboard

Effexor Xr is a drug marketed by Wyeth Pharms Inc and is included in one NDA. It is available from sixteen suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are sixty-four drug master file entries for this compound. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

Summary for Tradename: EFFEXOR XR

Patents:5
Applicants:1
NDAs:1
Suppliers: see list16

Clinical Trials for: EFFEXOR XR

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study
Status: Completed Condition: Healthy

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
Status: Active, not recruiting Condition: Bariatric Surgery; Gastric Bypass; Roux-en-Y Gastric Bypass

Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder
Status: Recruiting Condition: Depression

Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Status: Completed Condition: Unipolar Depression

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions
Status: Completed Condition: Healthy

Venlafaxine 25 mg Tablets Under Fasting Conditions
Status: Completed Condition: Healthy

Venlafaxine 25 mg Tablets Under Non-Fasting Conditions
Status: Completed Condition: Healthy

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer
Status: Terminated Condition: Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699Oct 20, 1997RXYes6,274,171*PED<disabled>Y<disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699Oct 20, 1997DISCNNo6,419,958*PED<disabled>Y<disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699Oct 20, 1997RXNo6,444,708*PED<disabled><disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699Oct 20, 1997RXNo5,916,923*PED<disabled><disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699Oct 20, 1997RXYes6,419,958*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EFFEXOR XR

Drugname Dosage Strength RLD Submissiondate
venlafaxine hydrochlorideExtended-release Tablets37.5 mg, 75 mg and 150 mgEffexor XR5/3/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc